Attovia Therapeutics (ATTO) Stock Analysis

What Attovia Therapeutics does

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Key metrics

ETFs linked to ATTO

Broad-market and Healthcare sector ETFs an investor holding Attovia Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ATTO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Attovia Therapeutics?

Attovia Therapeutics trades under the ticker ATTO on NASDAQ.

Which exchange is ATTO listed on?

ATTO is listed on NASDAQ.

What sector does Attovia Therapeutics operate in?

Attovia Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ATTO in a portfolio?

PortView shows ATTO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.